Rates of complete nonadherence among atypical antipsychotic drugs: A study using blood samples from 13,217 outpatients with psychotic disorders.

Schizophrenia Research
Robert L SmithEspen Molden

Abstract

Nonadherence to antipsychotics may cause relapse and hospitalizations in patients with psychotic disorders. The purpose was to quantify and compare the outpatient's nonadherence rates of atypical antipsychotics by objective detection in blood samples. Totally, 13,217 outpatients with therapeutic drug monitoring (TDM) data of atypical antipsychotics were included. An event of complete nonadherence was defined as an occurrence of undetectable level of a prescribed antipsychotic in the blood sample submitted for TDM. Patients with such an event(s) were defined as nonadherent of the respective drug treatment (outcome). The rates of nonadherence patients were compared between the drugs by logistic regression. In the study population, 70.2% of the patients were prescribed doses compliant with a schizophrenia diagnosis. The mean olanzapine equivalent dose in the population was 13.4 mg (95% confidence interval (CI): 13.3, 13.6). The frequency of nonadherence patients, regardless of drug, was 3.7% (CI: 3.4-4.0). The nonadherence patient rate was lowest in clozapine-treated patients (2.2%; CI: 1.5-2.8), followed by aripiprazole (2.3%; 1.7-2.8), risperidone (2.4%; 1.6-3.0), quetiapine (2.8%; 2.3-3.2) and olanzapine (4.9%; 4.1-5.3). Users ...Continue Reading

References

May 9, 1998·Psychiatric Services : a Journal of the American Psychiatric Association·J A Cramer, R Rosenheck
Dec 25, 2003·Schizophrenia Research·Peter J WeidenDiana D McDonnell
May 24, 2005·Medical Care·Michael C SokolRobert S Epstein
Aug 5, 2005·The New England Journal of Medicine·Lars Osterberg, Terrence Blaschke
Sep 21, 2005·The New England Journal of Medicine·Jeffrey A LiebermanUNKNOWN Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators
Aug 23, 2007·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Julia SacherSiegfried Kasper
Jun 4, 2010·Journal of Clinical Psychopharmacology·Halldóra JónsdóttirOle A Andreassen
Nov 1, 2012·Schizophrenia Bulletin·Bernadette A CullenGail L Daumit
Apr 11, 2013·Forensic Science International : Synergy·Danielle S FisherRobert J Flanagan
Jul 23, 2013·Patient Preference and Adherence·Jacqueline G HugtenburgLiset van Dijk
Feb 5, 2014·Schizophrenia Bulletin·Stefan LeuchtJohn M Davis
Jul 16, 2014·World Journal of Psychiatry·Subho Chakrabarti
Jul 26, 2014·Patient Related Outcome Measures·Peter M HaddadJan Scott
Oct 27, 2017·Acta Psychiatrica Scandinavica·R McCutcheonO D Howes
Dec 14, 2018·Lancet·Richard KonesAlberto Morales-Salinas
Nov 27, 2019·Schizophrenia Research·Dawn I VelliganCandace Wright

❮ Previous
Next ❯

Citations

Jul 1, 2020·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Robert L SmithEspen Molden
Sep 1, 2021·Expert Opinion on Drug Metabolism & Toxicology·Espen Molden

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Related Papers

American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons
J J Curtis
Journal of the American Pharmaceutical Association : APhA
M M Dardis
Archives of Internal Medicine
Jihad Irani
The American Journal of Pharmacy Benefits
Geoffrey F Joyce
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology
Robert L SmithEspen Molden
© 2021 Meta ULC. All rights reserved